Seeing Is Believing
Currently out of the existing stock ratings of Thomas Shrader, 94 are a BUY (90.38%), 10 are a HOLD (9.62%).
Analyst Thomas Shrader works at BTIG with a stock forecast success ratio of 46.11% fulfilled within 197.53 days on average.
Thomas Shrader’s has documented 207 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BHVN, Biohaven Pharmaceutical Holding Co Ltd at 09-Jan-2024.
Analyst best performing recommendations are on SLN (SILENCE THERAPEUTICS PLC).
The best stock recommendation documented was for VRNA (VERONA PHARMA PLC ADR) at 12/20/2022. The price target of $26 was fulfilled within 10 days with a profit of $7.41 (39.86%) receiving and performance score of 39.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
60
$29.14 (94.43%)
50
18 days ago
1/4 (25%)
$31.06 (107.33%)
244
Buy
47
$16.14 (52.30%)
47
25 days ago
6/11 (54.55%)
$14.65 (45.29%)
327
Buy
46
$15.14 (49.06%)
42
1 months 6 days ago
1/2 (50%)
$12 (35.29%)
50
Buy
60
$29.14 (94.43%)
60
7 months 1 days ago
6/11 (54.55%)
$31.33 (109.28%)
240
Buy
38
$7.14 (23.14%)
42
7 months 12 days ago
10/11 (90.91%)
$9.59 (33.76%)
136
Which stock is Thomas Shrader is most bullish on?
Which stock is Thomas Shrader is most reserved on?
What Year was the first public recommendation made by Thomas Shrader?